

# PREDICT®

Pharmacological qualification of anticancer agents.

## DRUG SCREENING, LEAD AND CLINICAL CANDIDATE SELECTION

- Drug formulation for *in vivo* administration
- Mechanism of action determination
- PK profiling and PD biomarker identification
- Dose and schedule optimization
- Drug combination evaluation
- Drug efficacy and resistance evaluation

### A comprehensive platform of cancer assays for early drug discovery:

- Target identification and validation
- Drug cytotoxicity, apoptosis, proliferation, migration, invasion and signal transduction assessment
- Drug metabolism studies
- Evaluation of complement dependent cyto toxicity (CDC) and antibody dependent cell cytotoxicity (ADCC) drug effects

For each of your preclinical research projects, a scientific team is appointed to design your project and conduct your study.

### Choose the most relevant model and design your preclinical trial.

Our platform offers a large panel of validated models appropriate for your drug target or therapeutic indication:

- More than 400 cell lines
- Xenogeneic, syngeneic, ectopic, orthotopic or metastatic *in vivo* models

- Rat cancer models: more than 150 subcutaneous and orthotopic xenogeneic or syngeneic rat tumor models, including chemically induced and patient-derived tumor models
- Humanized models: patient-derived xenografts, and/or humanized immune system in mice
- *Ex vivo* drug efficacy testing on patient's tumors

### Technologies and scientific expertise.

Our PhD-led team works with you to select the most appropriate program design and screening method to conduct preclinical assays.

A large panel of techniques are routinely used, such as preclinical formulation, automated *in vitro* screening of cytotoxicity, cytometry, molecular biology, angiogenesis assays, drug formulation, histopathology and immunohistochemistry, long term

*in vivo* infusion, microsurgery, analytical chemistry for PK, biodistribution and metabolism of compounds, and imaging of drug efficacy. All assays are standardized with reference drugs and positive controls for quality assurance.

Directly benefit from 19 of experience in preclinical *in vitro* / *in vivo* evaluation of therapeutic drug efficacy available at Oncodesign.

For more information email [contact@oncodesign.com](mailto:contact@oncodesign.com)

[www.oncodesign.com](http://www.oncodesign.com)

PREDICT® is part of a comprehensive portfolio of translational rodent models and services offered by Oncodesign.

